Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference
Palvella Therapeutics will present posters with previously reported Phase 3 SELVA and Phase 2 TOIVA results for QTORIN rapamycin, plus new pediatric analyses, at the PeDRA Annual Conference on October 15–17, 2026. The pediatric analyses highlight improvements in overall disease severity and lesion characteristics in children with microcystic lymphatic malformations and cutaneous venous malformations.
Key figures
- Drug Name
- QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin)
- Phase Of Trial
- Phase 3 (SELVA) and Phase 2 (TOIVA)
- Conference
- PeDRA Annual Conference
- Poster numbers
- ["036","035"]
- Conference dates
- October 15–17, 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.